Multi-omics diagnostic panels for precision oncology

Multi-omics diagnostic panels for precision oncology combine multiple molecular data layers — genomic, transcriptomic and increasingly proteomic — from a single tumor or blood sample into an integrated profile, going beyond a single drug-label companion diagnostic to inform the full range of a patient’s treatment options. Tempus AI has launched its first whole-genome sequencing assay (xH) and a novel pan-cancer homologous-recombination-deficiency (HRD) RNA algorithm, building on its comprehensive genomic profiling panel used across a value-based community oncology network. Caris Life Sciences launched Caris Detect and introduced AI-powered molecular insights for non-small-cell lung cancer patients, alongside AI models predicting brain-metastases risk in breast and lung cancer, its Caris ChromoSeq assay, and its Caris Assure blood-based test — combining genomic, transcriptomic and proteomic layers into an integrated molecular profile. Sophia Genetics’ SOPHiA DDM platform signed a strategic collaboration with a leading global cancer center and launched AI-powered digital twins to enhance oncology treatment decision-making, alongside a Mount Sinai Health System collaboration. In China, Geneseeq Technology participates in the country’s precision-oncology genomic testing market. In India, 1cell.ai offers multi-omic oncology products including OncoIndx, OncoIndx 360, OncoTarget and Prime Plus.

The key directions of multi-omics diagnostic panels for precision oncology are:

1. AI-driven multi-omic sequencing platforms (AI Multi-Omic Sequencing): whole-genome and RNA-algorithm-based sequencing platforms generating a comprehensive genomic profile beyond a targeted gene panel — Tempus AI’s xH assay and pan-cancer HRD RNA algorithm.
2. Integrated genomic-transcriptomic-proteomic profiling (Integrated Molecular Profiling): combining DNA, RNA and protein-level data from a single sample into one treatment-matching report — Caris Life Sciences’ Caris Detect and Caris Assure.
3. Multi-omic data analytics for treatment decisions (Multi-Omic Decision Analytics): AI-powered platforms that integrate multi-omic data into digital-twin or decision-support tools for oncologists — Sophia Genetics’ SOPHiA DDM.
4. Regional multi-omic oncology panels (Regional Multi-Omic Panels): domestic multi-omic testing platforms adapted to local clinical and regulatory context — Geneseeq Technology, 1cell.ai.

Sectoral value chain#

[tumor/blood sample collection] ──> [multi-omic sequencing & profiling (DNA+RNA+protein)] ──> [AI/bioinformatics integration]
                                                    │
                                       (treatment-matching report generation)
                                                    │
                                                    ▼
[oncologist treatment decision & outcome tracking] <─── [regulatory status (LDT/IVDR/NMPA)] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Whole-genome and RNA-algorithm sequencing (AI Multi-Omic Sequencing): sequencing beyond a targeted gene panel captures a broader mutational and expression landscape, as in Tempus AI’s xH whole-genome assay and pan-cancer HRD RNA algorithm.
• Integrated multi-layer molecular profiling (Integrated Molecular Profiling): combining DNA, RNA and protein data from one sample, Caris Life Sciences’ core approach, surfaces treatment options a single-layer test would miss.
• AI decision-support and digital twins (Multi-Omic Decision Analytics): Sophia Genetics’ digital-twin technology models a patient’s likely treatment response from their multi-omic profile to support oncologist decision-making.

The stack layers whole-genome/RNA sequencing, multi-layer molecular profiling and AI decision-support analytics to turn a single sample into a treatment-matching report spanning far more therapy classes than a single-marker test could reach.

1. Whole-genome and RNA-algorithm sequencing (AI Multi-Omic Sequencing):
   • Tempus AI’s xH assay and pan-cancer HRD RNA algorithm extend genomic profiling beyond a targeted panel, capturing the fuller mutational and expression landscape used across its community oncology network.
2. Integrated genomic-transcriptomic-proteomic profiling (Integrated Molecular Profiling):
   • Caris Life Sciences combines DNA, RNA and protein-level data from a single sample (Caris Detect, Caris Assure, Caris ChromoSeq) into one report, with AI models further predicting risks such as brain metastases in breast and lung cancer.
3. AI-powered digital twins and decision support (Multi-Omic Decision Analytics):
   • Sophia Genetics’ SOPHiA DDM platform builds AI-powered digital twins from a patient’s multi-omic profile to model likely treatment response, deployed through direct collaborations with leading cancer centers.
4. Regional multi-omic testing capacity (Regional Multi-Omic Panels):
   • Geneseeq Technology and 1cell.ai build domestic multi-omic oncology testing capacity adapted to their respective markets in China and India.